In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075 and 0.15 mg/kg twice weekly (1.9-, 9.9- and 29-fold the MRHD) were administered throughout organogenesis, from Gestation Day 16 to 50
No tapering or special transition is needed because the total weekly drug exposure does not change
Pocai A
Plan ahead for your meals and snacks to avoid impulsive and unhealthy food choices
Use of GLP-1RAs and SGLT2is is influenced by cost, insurance coverage, access to care, and structural barriers, with lower use observed among socioeconomically disadvantaged individuals and racial and ethnic minority groups [56, 59, 60]
There may be situations where people could stop taking semaglutide abruptly without significant adverse effects (outside of weight gain)